Patients with NMSC – a registry-based cohort study
EUMelaReg has started a registry-based cohort study and presented an e-poster at EADO 2023 on “Modern Treatment Usage and Outcome of Patients with Advanced Non-Melanoma Skin Cancer (NMSC) – a Registry Based Cohort Study.”
Among NMSC, basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) are the predominant histologic subtypes. Real-world data systematically recorded in registries are limited. Many cancer databases do not register NMSCs at all. For patients with advanced NMSC, the EUMelaReg consortium (EMR) introduced a registry for NMSC across Europe. The aim of this registry is to collect real-world data of the available tumor and treatment patterns of advanced NMSC patients at a European level. Data of the EMR NMSC-Registry can be used for specific analyses regarding drugs, availability, and affordability of various treatments for different patient populations, data on health-related resource utilization, and patient outcomes. It is of importance to have a comprehensive picture on various treatments, or non-treatment strategies across Europe.
If you are interested in participating in the NMSC study, please contact firstname.lastname@example.org. For more detailed information please visit https://beta.clinicaltrials.gov/study/NCT05741073